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in 17,952 patients per group. Compared with control patients, AD patients had 
significantly more PPPY health care consumption in inpatient (0.70 vs. 0.28), emer-
gency room (0.67 vs. 0.31), ambulatory care (5.38 vs. 3.67), prescriptions (34.15 vs. 
23.84), Skilled Nursing Facility (SNF) (0.91 vs. 0.15), Home Health Agency (HHA) 
(0.53 vs. 0.23) and hospice (1.22 vs. 0.16). AD patients incurred significantly higher 
inpatient ($7,250 vs. $3,201), pharmacy ($4,131 vs. $2,266), SNF ($5,411 vs. $1,012), 
HHA ($1,559 vs. $641), hospice ($4,505 vs. $546) and total costs ($29,176 vs. $12,116; 
all p-values< 0.0001). ConClusions: AD is associated with a significantly higher 
economic burden compared to a control cohort.
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objeCtives: Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with 
interferon beta (IFNβ ) can develop neutralizing antibodies (NAbs) that reduce 
treatment efficacy. Several clinical studies explored the association of NAb+ sta-
tus with increased disease activity. The impact of NAbs on costs has not been 
explored. The aim of this study was to estimate the cost of RRMS patients who 
develop NAbs while treated with IFNβ by the Italian National Healthcare Service 
(NHS) and the Italian Society perspectives. Methods: The study was based on a 
mixed method approach, based on both already published observational clinical 
data from an Italian study in Bari of 546 RRMS patients treated with IFNβ , and 
cost data derived from the published literature. Direct and indirect costs were 
applied stratifying patients by EDSS 0-3 and 4-6. The average rate of NAbs in IFNβ 
treated patients calculated in the Italian observational study was applied to the 
current Italian MS population treated with IFNβ . The values were inflated to Euro 
2014. Results: The direct cost per patient was estimated as € 15,428 for the NAb+ 
and € 14,317 for the NAb-. The annual societal cost per patient was estimated as 
€ 33,890 for the NAb+ and € 30,790 for the NAb-. The increase of the total annual 
costs specifically due to the NAb+ status was € 3,100 from the Italian societal 
perspective and € 1,111 from the Italian NHS perspective. Applying the average 
NAbs incidence rate, calculated in the Italian observational study (13.7%), to the 
current Italian MS population treated with IFNβ the total annual cost increases 
of approximately 3.5 million from the NHS perspective and 9.9 million from the 
societal perspective. ConClusions: The results of this economic evaluation sug-
gest the association between Nab+ status and increased costs for the management 
of RRMS. Further pharmacoeconomic research will be needed to confirm this first 
result.
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objeCtives: The purpose of this study was to estimate the economic burden 
of brain disorders and provide relevant information to support health policy for 
people with brain disorders in Korea. Methods: The economic burden of brain 
disorders in Korea was estimated on the basis of direct and indirect costs using a 
prevalence-based approach. Data were retrieved from the nationwide databases 
between 2008 and 2011: Korea National Health Insurance Corporation, the National 
Disability Registry of Ministry of Health and Welfare, the Korea National Statistical 
Offices’ records of cause of death. The direct costs were those that result from pri-
mary medical and non medical expenses directly associated with brain disorders 
such as caregiver and transportation costs. The indirect costs referred to costs of 
lost opportunity due to premature death and productivity loss and a 3% discount 
rate was applied for the calculation. Results: The prevalence of brain disorders 
increased from 0.26% to 0.35% for the years 2008-2011. Total economic burden of 
brain disorders substantially increased from $1.88 billion (2008) to $2.90 billion 
(2011) by explaining approximately 54% increments of economic burden, which 
represented 0.3% of the Korean gross domestic product. According to proportion 
of costs over total economic burden, direct medical costs were increased (from 
46.4% to 59.9%) and indirect costs were decreased (from 53.6% to 40.1%) between 
2008 and 2011. By gender, male was higher burden than female approximately 
1.4~1.5 times during 2008~2011. By age groups, the cost of brain disorders was 
the highest burden aged 50 to 59 in 2011. ConClusions: The results showed 
that the prevalence and economic burden estimated from direct costs of brain 
disorders increased for the years 2008~2011. The findings supported needs of 
additional health care services and rehabilitation programs for people with brain 
disorders in Korea.
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objeCtives: In the UK, the MHRA discourages generic prescribing of certain antie-
pileptics. However, epilepsy charities advocate for greater branded prescribing, espe-
cially for antiepileptics in MHRA categories 2 and 3. We estimated: - Cost-savings 
achievable if antiepileptic prescriptions were always issued for the cheapest com-
parable drug - Additional cost if only prescribing branded antiepileptics. Methods: 
Data showing the number of antiepileptic prescriptions issued in English and Welsh 
general practices in 2014, and the associated net ingredient cost (NIC), were sourced 
from the HSCIC and NHS Wales and analysed using a proprietary in-house software. 
warranted. The study was supported by Biogen and the Swedish Research Council 
for Health, Working Life and Welfare.
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objeCtives: To assess annual health care resource utilization and direct medical 
costs for patients with epilepsy in Tianjin, China. Methods: Cross-sectional data 
were obtained from 30% random sampling Urban Employee Basic Medical Insurance 
(UEBMI) claims of Tianjin from each year of 2008 to 2013. The epileptic patients with 
≥ 1 diagnosis of epilepsy (ICD-10-CM G40/G41) before and in each calendar year were 
selected. All-cause and epilepsy-related health care resource utilization and costs of 
inpatient, outpatient and special outpatient service were assessed and comparisons 
were further conducted between “refractory” patients (treated with ≥ 3 antiepileptic 
drugs in study period) and “non-refractory” patients (treated with ≤ 2 antiepilep-
tic drugs in study period) using t-tests and chi-square tests. Results: Over 5-year 
period (from 2009 to 2013), the prevalence increased from 0.84‰ to 3.05‰. The sam-
ple patients aged 57.1 years, with 43.0% female and 15.9% of refractory in 2013. For 
epilepsy-related health services, 17.6% of patients experienced ≥ 1 hospitalizations 
in 2013, with decreased mean length of stay (2009: 48.5, 2013: 35.0), 83.8% of patients 
experienced ≥ 1 outpatient visits in 2013, while the corresponding proportions for 
special outpatient visits were 13.4% with increased mean number of visits (2009:3.6, 
2013:14.0). The epilepsy-related costs per patient decreased from 2009 ($1346) to 
2013 ($1130), among them the drug costs were the largest component (60.0%), fol-
lowed by therapeutic costs (15.4%) and examination costs (12.9 %). The all-cause 
costs stay relatively constant and were $2834 in 2013. Refractory cohort incurred 
significantly higher epilepsy-related costs than non-refractory cohort ($2237 vs $921, 
P< 0.001, 2013), which was driven by higher hospitalization rates (26% vs. 16%, P< 0.001, 
2013). ConClusions: A decreased trend of annual epilepsy-related costs over a five-
year period was associated with the less uses of inpatient services. Refractory epilepsy 
patients had as twice as much the cost of non-refractory patients.
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objeCtives: The aim of the study was to assessed the indirect costs associated 
with multiple sclerosis (MS) from the perspective of the Social Insurance Institution 
(ZUS) in Poland. Methods: The estimates were based on data from the Social 
Insurance Institution referring to year 2013 and focused on absenteeism due to 
the illness: costs of sick leave, short-term disability due to rehabilitation benefit 
and the burden of permanent (or long-term) disability due to disability pension in 
Poland. Cost analysis was performed based on the Human Capital Approach taking 
into account Gross Domestic Product (GDP) per capita (10 278 EUR) and Gross Value 
Added (GVA) per worker (24 680 EUR). Results: Total indirect costs of MS associated 
with absenteeism in the year 2013 in Poland were 73 633 786 EUR (GDP per capita) 
and 176 816 568 EUR (GVA per worker). The predominant component of absentee-
ism of MS was long-term disability (88%). Sick leave and short-term disability costs 
constituted 9% and 3% of total indirect costs of MS associated with absenteeism, 
respectively. One sick leave of person with MS generated the cost of lost productivity 
equal 451 EUR and 1 082 EUR calculated using GDP per capita and GVA per worker, 
respectively. Indirect cost of short-term disability for one entitlement to the benefit 
of rehabilitation were 4 506 EUR and 10 821 EUR, respectively. Cost of one long-term 
benefit equaled for limited period 23 866 EUR (GDP per capita) and 57 308 EUR (GVA 
per worker), and unlimited period 359 257 EUR (GDP per capita) and 862 683 EUR 
(GVA per worker) respectively. ConClusions: MS in Poland generated very high 
indirect costs. The main component was long-term disability; sick leave and reha-
bilitation benefit generated lower costs of lost productivity.
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objeCtives: Examine the economic burden and healthcare utilization of patients 
diagnosed with Alzheimer’s disease (AD). Methods: Patients diagnosed with 
AD (International Classification of Diseases, 9th Revision, Clinical Modification 
code 331.0 and ≥ 1 anti-AD prescription [donepezil, rivastigmine, galantamine, 
memantine] or a second AD diagnosis) were identified using 5% national Medicare 
data (01JAN2010–31DEC2012). The index date was the first AD diagnosis date. A 
control group was created by identifying patients without AD, AD-related dementia 
or anti-AD prescriptions using 1:1 matching based on age, gender, race, region 
and study year. The same index date and follow-up length were assigned to each 
matched pair. Patients were required to be aged 65-100 years, with continuous 
medical and pharmacy benefits for 24 months pre- and 6 months post-index date, 
and were followed until the earliest date of death, disenrollment or study end. 
One-to-one propensity score matching (PSM) were used to compare follow-up 
healthcare utilization and costs per-patient-per-year (PPPY) between the AD and 
control groups, controlling for demographics, clinical characteristics and baseline 
health-care costs. Results: A total of 96,738 patients were identified for both 
cohorts, with an average age of 83 years and 620 days follow-up. PSM resulted 
